3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane bromide monohydrate structure
|
Common Name | 3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane bromide monohydrate | ||
---|---|---|---|---|
CAS Number | 66985-17-9 | Molecular Weight | 414.377 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C20H32BrNO3 | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | N/A | |
Symbol |
GHS07 |
Signal Word | Warning |
Use of 3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane bromide monohydrateIpratropium bromide (Sch 1000) hydrate is a muscarinic receptor antagonist, with IC50s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide hydrate relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma[1][2][3][4][5]. |
Name | ipratropium bromide hydrate |
---|---|
Synonym | More Synonyms |
Description | Ipratropium bromide (Sch 1000) hydrate is a muscarinic receptor antagonist, with IC50s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide hydrate relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma[1][2][3][4][5]. |
---|---|
Related Catalog | |
Target |
muscarinic M1 receptor:2.9 nM (IC50) muscarinic M2 receptor:2 nM (IC50) muscarinic M3 receptor:1.7 nM (IC50) |
In Vitro | Ipratropium bromide hydrate (1 nM, 10 nM, 100 nM; 15 min) exerts its toxic effects via disruption of mitochondrial membrane potential[1]. Ipratropium bromide hydrate (1 nM-1 μM; 4 h) increases infarct size in isolated perfused heart ischaemia/reperfusion experiments with a dose-responsive manner (EC50=22.7 nM)[1]. Ipratropium bromide hydrate (0.001 nM-0.1 mM; 2 h) inhibits adult rat cardiac myocyte growth after 4 h hypoxia treatment[1]. Cell Viability Assay[1] Cell Line: Adult Rat Cardiac Myocyte Concentration: 0.001 nM-0.1 mM Incubation Time: 2 h in dark; prior to 4 h hypoxia Result: Resulted cell viability in a dose-dependent manner, with the inhibition rate of 52.7% at 0.1 mM dose. |
In Vivo | Ipratropium bromide hydrate (1.0 μg/kg; i.v.; single dose) enhances vagal nerve stimulation induing bronchoconstriction[2]. Ipratropium bromide hydrate (0.04 mg/20 mL and 0.20 mg/20 mL; inhalation for 30 min, rate=30 mL/30 min) can protect the lungs against the cadmium-induced acute neutrophilic inflammation by reducing the parenchyma inflammatory infiltration of neutrophils[4]. Animal Model: Guinea-pigs of the Dunkin Hartley strain[2] Dosage: 0.1-1 μg/kg Administration: Intravenous injection; single dose Result: Resulted little blocking effect on post-junctional muscarinic receptors at 0.3 μg/kg, and inhibited ACh-induced bronchoconstriction at 0.5 μg/kg. Animal Model: Male Sprague-Dawley rats (300-350 g)[4] Dosage: 0.04 mg/20 mL and 0.20 mg/20 mL Administration: Inhalation; atomization rate of 30 mL/30 min; 30 min Result: Had no significant effects on any parameters recorded in healthy rats but exerted a protective effect against the inflammatory reaction elicited by cadmium. |
References |
Molecular Formula | C20H32BrNO3 |
---|---|
Molecular Weight | 414.377 |
Exact Mass | 413.156555 |
PSA | 46.53000 |
LogP | 0.02610 |
Appearance of Characters | white |
Water Solubility | H2O: soluble10mg/mL |
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H302 + H332-H319 |
Precautionary Statements | P261-P301 + P312 + P330-P305 + P351 + P338 |
Hazard Codes | Xn |
Risk Phrases | 20/22-36 |
Safety Phrases | 26 |
RIDADR | NONH for all modes of transport |
RTECS | YM3700000 |
HS Code | 2933990090 |
HS Code | 2933990090 |
---|---|
Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Fast targeted analysis of 132 acidic and neutral drugs and poisons in whole blood using LC-MS/MS.
Forensic Sci. Int. 243 , 35-43, (2014) The aim of this study was to develop an LC-MS/MS based screening technique that covers a broad range of acidic and neutral drugs and poisons by combining a small sample volume and efficient extraction... |
|
Nebulization of active pharmaceutical ingredients with the eFlow(®) rapid: impact of formulation variables on aerodynamic characteristics.
J. Pharm. Sci. 103(8) , 2585-9, (2014) Nebulization of active pharmaceutical ingredient (API) solutions is a well-established means to achieve pulmonary drug deposition. The current study identified the impact of formulation variables on t... |
|
4R-cembranoid protects against diisopropylfluorophosphate-mediated neurodegeneration.
Neurotoxicology 44 , 80-90, (2014) Many organophosphorous esters synthesized for applications in industry, agriculture, or warfare irreversibly inhibit acetylcholinesterase, and acute poisoning with these compounds causes life-threaten... |
Ipratropium Bromide Monohydrate |
8-Azoniabicyclo[3.2.1]octane, 3-(3-hydroxy-1-oxo-2-phenylpropyl)-8-methyl-8-(1-methylethyl)-, bromide, (3-endo), hydrate (1:1:1) |
(3-endo)-3-(3-Hydroxy-2-phenylpropanoyl)-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane bromide hydrate (1:1:1) |
3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane bromide monohydrate |